:

United States

United States

Choose language: English

EIF2AK2 Kinase Enzyme System

V4492

Easily Screen and Profile EIF2AK2 Kinase Inhibitors

  • Includes kinase, substrate and reaction buffer
  • Use with ADP-Glo™ Assay for bioluminescent detection of kinase activity

Size

Additional options

Catalog number selected: V5328

$ 435.00 Your price: Log In

EIF2AK2 Kinase Enzyme System
10µg
$ 435.00
Your price: Log In
Change Configuration
Kinase-background-v2light

Convenient, Scalable Kinase Profiling

The Kinase Enzyme Systems include a recombinant kinase enzyme, a substrate appropriate for the enzyme, a reaction buffer and supplemental reagents as needed. The EIF2AK2 Kinase Enzyme System contains:

  • EIF2AK2 Kinase, 10μg (Human, recombinant; amino acids 252–end). MW: ~64kDa.
  • Native Swine Myelin Basic Protein (MBP) Substrate.
  • Reaction Buffer, DTT.

Recombinant human EIF2AK2 (252–end) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag. EIF2AK2 (also known as double-stranded RNA-activated protein kinase) is a protein kinase shown to be involved in HIV/gp120-associated neurodegeneration. EIF2AK2 acts as a critical mediator of gp120 neurotoxicity and is a substrate for a family of protein kinases that respond to various forms of environmental stress. Activation of EIF2AK2 leads to its autophosphorylation and then phosphorylation of its natural substrate, the alpha subunit of eukaryotic protein synthesis initiation factor-2. EIF2AK2 plays a critical role in mRNA translation, cell proliferation and apoptosis. A novel cross-talk event between the EIF2AKs and p53 has been shown that has implications in cell proliferation and tumorigenesis.

EIF2AK2 NCBI Database Entry.

The EIF2AK2 Kinase Enzyme System can be purchased with or without the ADP-Glo™ Kinase Assay reagents. Used together, the ADP-Glo™ Kinase Assay + Kinase Enzyme Systems provide a convenient method for profiling the effect of lead compounds on kinase activity. Assay advantages include broad dynamic range, ease of use and high sensitivity. Kinase Enzyme Systems are manufactured by SignalChem. Bulk quantities available upon request.

Use with ADP-Glo™ Kinase Assay

The ADP-Glo™ Kinase Assay is a luminescent kinase assay that measures ADP formed from a kinase reaction; ADP is converted into ATP, which is a substrate in a reaction catalyzed by Ultra-Glo™ Luciferase that produces light. The luminescent signal positively correlates with ADP amount and kinase activity. The assay is well suited for measuring the effects of chemical compounds on the activity of a broad range of purified kinases, making it ideal for both primary screening as well as kinase selectivity profiling. The ADP-Glo™ Kinase Assay can be used to monitor the activity of virtually any ADP-generating enzyme (e.g., kinase or ATPase) using up to 1mM ATP.

 

See all Kinase Enzyme Systems available from Promega.

Protocols

Specifications

You are viewing: V5328 Change Configuration

SDS

Choose language:

Certificate of Analysis

Search for Specific Certificate:

View more results
No results
Loading…

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

AA

Specifications

You are viewing: V6585 Change Configuration

SDS

Choose language:

Certificate of Analysis

Search for Specific Certificate:

View more results
No results
Loading…

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

AA

Specifications

You are viewing: V5329 Change Configuration

What's in the box?

Item Part # Size

EIF2AK2 Kinase Enzyme System

V5328 1 × 10μg

ADP-Glo™ Kinase Assay

V9101 1 × 1,000 assays

SDS

Choose language:

Certificate of Analysis

Search for Specific Certificate:

View more results
No results
Loading…

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

Patents and Disclaimers

U.S. Pat. Nos. 7,083,911, 7,452,663 and 7,732,128 and other patents.

U.S. Pat. No. 7,700,310 and other patents and patents pending.

U.S. Pat. Nos. 7,741,067, 8,361,739 and 8,603,767 and other patents and patents pending.

U.S. Pat. Nos. 6,602,677, 7,241,584, 8,030,017 and 8,822,170 and other patents and patents pending.

U.S. Pat. No. 8,183,007 and other patents and patents pending.

Licensed from Lonza Nottingham Ltd. under U.S. Pat. Nos. 6,599,711 and 6,911,319 and other pending and issued patents.

Resources

Choose your country

Americas

Brazil
Brazil
Canada
Canada
United States
United States

Pacific Asia

Australia
Australia
India
India
Japan
Japan
Korea, Republic of
Korea, Republic of
Singapore
Singapore

Europe

Austria
Austria
Belgium
Belgium
Denmark
Denmark
Estonia
Estonia
Finland
Finland
France
France
Germany
Germany
Iceland
Iceland
Italy
Italy
Luxembourg
Luxembourg
Netherlands
Netherlands
Norway
Norway
Poland
Poland
Spain
Spain
Sweden
Sweden
Switzerland
Switzerland
United Kingdom
United Kingdom